How Is AHI Scaling Global Digital Health Amid ASX Suspension and NASDAQ Delisting?

Strategic Commercial Momentum Despite Market Suspension

Advanced Health Intelligence Ltd (ASX, AHI) has delivered one of its most commercially active quarters to date, advancing its global digital health footprint even as its securities remain suspended from trading on the ASX. The company’s proprietary health screening technologies have gained traction through binding agreements and commercial term sheets spanning the United States, Asia, and the Middle East and North Africa (MENA) region.

AHI’s partner Bearn LLC launched the HIQOR platform in March 2025, integrating AHI’s technology into major US health and insurance markets. This milestone was complemented by the company’s first commercial insurance deployment with Unisure in the UK, where AHI’s Digital Health Assessment supports underwriting and policyholder engagement, marking a significant validation of its product in a sector ripe for digital transformation.

Intellectual Property and Technology Validation

In a notable intellectual property achievement, AHI was granted a US patent titled “Assessing Disease Risks from User-Captured Images,” reinforcing its leadership in mobile digital health innovation. This patent protects AHI’s unique AI-driven methods for assessing risks of metabolic, cardiovascular, and obesity-related diseases through smartphone-captured images, positioning the company as a gatekeeper in the burgeoning AI-enabled healthcare diagnostics market.

Further bolstering its technology credentials, AHI’s flagship Digital Health Check was listed on the Microsoft Azure Marketplace, and the company was accepted into the Microsoft ISV Success Program. These endorsements not only affirm the security and scalability of AHI’s platform but also open new avenues for global adoption through Microsoft’s enterprise ecosystem.

Funding and Financial Position

To underpin its growth and ASX reinstatement strategy, AHI secured a USD 4 million cornerstone investment from UAE-based KOR Holdings and is actively pursuing an additional USD 6 million in funding. While KOR Holdings has faced delays in fund release, both parties remain committed to resolving these issues and establishing a revised payment schedule.

Complementing equity funding, AHI is progressing multiple Research & Development (R&D) tax incentive claims with AusIndustry, expecting reimbursements totaling approximately AUD 3 million in non-dilutive capital. This financial support is critical as the company navigates operational challenges and prepares for a return to trading.

Navigating Regulatory and Market Challenges

AHI’s NASDAQ listing was formally delisted in July 2025 following a prolonged suspension due to shareholder equity deficiencies. The company’s immediate focus is on meeting ASX reinstatement requirements, including finalising audited financial statements and securing sufficient operational funding. Successful ASX reinstatement is a prerequisite for pursuing NASDAQ relisting or a fresh US listing, which remains a key strategic objective.

Despite these regulatory hurdles, AHI’s commercial partnerships continue to advance. Collaborations with partners such as Vitall in Canada, Pharmak in the UAE, Kalibra in Singapore, and Upvio Healthtech demonstrate the broad applicability and growing demand for AHI’s digital health solutions across diverse markets.

Outlook and Strategic Positioning

With multiple commercial deployments underway and a validated technology suite, AHI is poised to accelerate revenue growth and achieve cashflow breakeven in 2025. The company’s leadership highlights the growing global demand for scalable, AI-driven health screening tools that enable early detection and personalised intervention.

While geopolitical factors such as US tariff schedules have introduced short-term uncertainties, AHI remains focused on long-term value creation through strategic partnerships and global expansion. The company’s evolving platform, including innovations like the AF-Scan for atrial fibrillation detection, positions it at the forefront of digital health transformation.